Advertisement

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Oct

30

Today In Oncology

How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation

Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC

TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer

Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs

Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy

Advertisement

© 2026 HSP News Service, L.L.C.